Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30216
Title: | Lab-in-a-van: Rapid SARS-CoV-2 testing response with a mobile laboratory. | Austin Authors: | Ballard, Susan A;Graham, Maryza;David, Debra;Hoang, Tuyet;Donald, Angela;Sait, Michelle;Isles, Nicole;Matlock, Amelia;Yallop, Sarah;Bek, Mark;Howden, Benjamin P ;Stinear, Timothy P | Affiliation: | Infectious Diseases Microbiological Diagnostic Unit Public Health Laboratory, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia Department of Health, State Government of Victoria, Australia Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia Department of Microbiology and Infectious Diseases, Monash Health, Clayton, Victoria 3168, Australia Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia |
Issue Date: | May-2022 | Date: | 2022-04-08 | Publication information: | EBioMedicine 2022; 79: 103983 | Abstract: | High testing rates and rapid contact tracing have been key interventions to control COVID-19 in Victoria, Australia. A mobile laboratory (LabVan), for rapid SARS-CoV-2 diagnostics, was deployed at sites deemed critical by the Victorian State Department of Health as part of the response. We describe the process of design, implementation, and performance benchmarked against a central reference laboratory. A BSL2 compliant laboratory, complete with a class II biological safety cabinet, was built within a Mercedes-Benz Sprinter Panel Van. Swabs were collected by on-site collection teams, registered using mobile internet-enabled tablets and tested using the Xpert® Xpress SARS-CoV-2 assay. Results were reported remotely via HL7 messaging to Public Health Units. Patients with negative results were automatically notified by mobile telephone text messaging (SMS). A pilot trial of the LabVan identified a median turnaround time (TAT) from collection to reporting of 1:19 h:mm (IQR 0:18, Range 1:03-18:32) compared to 9:40 h:mm (IQR 8:46, Range 6:51-19:30) for standard processing within the central laboratory. During deployment in nine rural and urban COVID-19 outbreaks the median TAT was 2:18 h:mm (IQR 1:18, Range 0:50-16:52) compared to 19:08 h:mm (IQR 5:49, Range 1:36-58:52) for samples submitted to the central laboratory. No quality control issues were identified in the LabVan. The LabVan is an ISO15189 compliant testing facility fully operationalized for mobile point-of-care testing that significantly reduces TAT for result reporting, facilitating rapid public health actions. This work was supported by the Department of Health, Victoria State Government, Australia. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30216 | DOI: | 10.1016/j.ebiom.2022.103983 | ORCID: | 0000-0003-0237-1473 | Journal: | EBioMedicine | PubMed URL: | 35405388 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35405388/ | Type: | Journal Article | Subjects: | Mobile testing Point-of-care Rapid testing Real-time PCR SARS-CoV-2 Turnaround-time |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.